666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patientsSarah P. Blagden, David J. Harrison, Alison L. Dickson et al.|Annals of Oncology|2024Cited by 3
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Stefan N. Symeonides et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)Khurum Khan, T.R. Jeffry Evans, Uma Mukherjee et al.|Molecular Cancer Therapeutics|2023Cited by 1